Pfizer Stock

Pfizer EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Pfizer (PFE) as of Aug 10, 2026 is 15.39. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 14.84 — a change of 3.71% (higher).

EV/EBIT

15.39

YoY

3.71%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Pfizer is 2026 15.39 . EV/EBIT (Enterprise Value to EBIT) of Pfizer was 2025 14.84 . It decreases by 3.71% higher compared to the previous year.

The Pfizer EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
29.37 base
Jan 1, 2020
22.94 base
Jan 1, 2021
15.45 base
Jan 1, 2022
7.84 base
Jan 1, 2023
30.72 base
Jan 1, 2024
14.32 base
Jan 1, 2025
13.90 base
Jan 1, 2026 (e)
11.55 base
YEARPRICE-TO-EBIT
2026 est 11.55
2025 13.90
2024 14.32
2023 30.72
2022 7.84
2021 15.45
2020 22.94
2019 29.37
2018 16.52
2017 15.26
2016 20.92
2015 14.99
2014 14.15
2013 11.85
2012 10.28
2011 9.05
2010 7.96
2009 7.68
2008 7.29
2007 11.22
2006 12.44
Access this data via the Eulerpool API

Pfizer Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Pfizer's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Pfizer's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Pfizer's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Pfizer grows earnings faster than its peers.

Pfizer Stock analysis

What does Pfizer do? Pfizer Inc, one of the world's largest and most well-known pharmaceutical companies, has made significant advancements in the medical industry throughout its approximately 170-year history. The company is headquartered in New York City and has offices in over 150 countries. Pfizer was founded in 1849 by two cousins, Charles Pfizer and Charles Erhart, who opened their first factory in Brooklyn to produce pure crystalline chinasalt. They later expanded their business and began synthesizing chemical compounds, leading them to enter the pharmaceutical industry. In the following years, Pfizer made some significant discoveries, including the synthesis of antibiotics such as penicillin and terramycin. In the 1990s, the company expanded its portfolio and became a leading provider of prescription drugs, immunological medications, and animal health products. Today, the company focuses on three core areas: innovative health products, patented medications, and generic products. Pfizer invests millions of dollars in research and development of new and innovative treatment options, including cancer drugs, therapies for neurological disorders, cardiovascular diseases, and immunology products. Another important aspect of Pfizer's business model is its partnerships with other companies and organizations. The company works closely with universities, research institutions, governments, and other companies to form partnerships that allow for collaborative development of new products. Some of Pfizer's most well-known products include Viagra, Lipitor, Celebrex, Zoloft, and Lyrica. Viagra is used to treat erectile dysfunction in men. Lipitor is a cholesterol-lowering medication that reduces the risk of cardiovascular diseases. Celebrex is an anti-inflammatory medication used to treat pain and inflammation. Zoloft is an antidepressant used to treat various mental disorders. Lyrica is a prescription medication used to treat pain and seizures. In recent years, Pfizer has also taken a leading role in the development of vaccines against COVID-19, collaborating with the German company BioNTech to develop a promising vaccine candidate. The vaccine provides protection against the virus, particularly against severe illness. Over the years, the company has faced concerns regarding the use of medications, such as the scandal surrounding the pain reliever Vioxx, which was withdrawn in 2004 after being associated with an increased risk of cardiovascular diseases. Pfizer has since strengthened its research and development standards and partnerships to ensure the safety and efficacy of its products. In summary, Pfizer is a global player in the pharmaceutical industry. The company heavily invests in research and development of new products to provide innovative treatment options, secures patents, and simultaneously keeps its portfolio up-to-date with generic products to remain competitive in the industry. The company will continue to contribute to improving healthcare worldwide by developing lifesaving medications and vaccines that enable people to lead better lives. Pfizer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pfizer stock

EV/EBIT (Enterprise Value to EBIT) of Pfizer is 15.39 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Pfizer changed from 14.84 to 15.39, representing a 3.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Pfizer since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Pfizer with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Pfizer

All Key Metrics — Pfizer